Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, placebo-controlled, double-blind, phase 2a study to characterize the safety and pharmacokinetics of FBR-002 in patients hospitalized with moderate to severe COVID-19 and at risk of severe outcome

Next Previous
Search
Trial Profile

A randomized, placebo-controlled, double-blind, phase 2a study to characterize the safety and pharmacokinetics of FBR-002 in patients hospitalized with moderate to severe COVID-19 and at risk of severe outcome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FBR-002 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Fabentech

    • Most Recent Events

    • 28 Jul 2023 Status changed from recruiting to completed.
    • 17 Jul 2023 This trial has been completed in Greece, according to European Clinical Trials Database record.
    • 23 Mar 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top